close
Add to watchlist
Novavax Inc (NVAX) Healthcare, Biotechnology & Drugs
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing vaccines using its virus-like particle platform technology for infectious diseases. It develops vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, and Respiratory Syncytial Virus, as well as Varicella Zoster that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products, and other diagnostic products for the territory of India. Novavax, Inc. was founded in 1987 and is headquartered in Rockville, Maryland.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 1.38 |
| Volume | 566881 |
| Volume Avg | 854132 |
| 52 Week High | 2.73 |
| 52 Week Low | 1.13 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.20 |
| EPS change Q/Q | -16.67% |
| EPS change Q/Q Yr ago | -30% |
| EPS change Q/Q next Q est | -75% |
| EPS change Y/Y | -21.88% |
| REV change Q/Q | 700% |
| REV change Q/Q Yr ago | 700% |
| EPS next Q est | -0.04 |
| EPS next Y est | -0.14 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |